Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 159,000 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 159,000 shares of the biotechnology company's stock, valued at approximately $10,451,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of BioMarin Pharmaceutical at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in BioMarin Pharmaceutical by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company's stock worth $1,273,334,000 after acquiring an additional 93,531 shares during the period. Dodge & Cox increased its stake in shares of BioMarin Pharmaceutical by 6.1% in the 4th quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock worth $969,270,000 after purchasing an additional 847,917 shares in the last quarter. Capital Research Global Investors raised its holdings in BioMarin Pharmaceutical by 23.8% in the 4th quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock worth $853,944,000 after purchasing an additional 2,496,817 shares during the period. Norges Bank purchased a new position in BioMarin Pharmaceutical during the fourth quarter valued at $234,645,000. Finally, Geode Capital Management LLC lifted its position in BioMarin Pharmaceutical by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 3,288,778 shares of the biotechnology company's stock valued at $215,784,000 after purchasing an additional 28,728 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock traded down $0.15 during mid-day trading on Wednesday, reaching $56.64. 451,021 shares of the company's stock traded hands, compared to its average volume of 1,868,825. BioMarin Pharmaceutical Inc. has a 12-month low of $52.93 and a 12-month high of $94.85. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average of $60.47 and a two-hundred day moving average of $64.38. The company has a market cap of $10.86 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 0.61 and a beta of 0.27.

Insider Activity

In related news, CAO Erin Burkhart sold 1,295 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares of the company's stock, valued at $1,212,621.60. This trade represents a 7.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 3,354 shares of company stock valued at $216,269. 0.85% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BMRN shares. Wedbush restated an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Citigroup reduced their target price on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Oppenheimer raised shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price target on the stock in a report on Monday, February 24th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Finally, UBS Group raised their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.45.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.